Now available in its Third Edition, Asthma: Basic Mechanisms and Clinical Management has become the reference text in asthma. This highly successful text sheds new light on the basic physiological and molecular mechanisms of asthma, how current treatments work, and how best to apply the latest knowledge to control this important disease. The Third Edition has undergone radical revision and includes several new chapters. It retains the virtues of the previous volumes by bringing together all of the recent research findings by internationally recognized experts on the causative mechanisms of asthma, including in-depth clinical aspects and therapy. The book presents an integrated approach toward the treatment of this disease with new concepts, changes in asthma management, and the development of new therapeutic agents. Asthma provides extensive references for researchers and clinicians who need to keep abreast of recent developments in this rapidly expanding field.
- Comprehensive coverage of both basic science and clinical aspects of asthma
- Extensively referenced throughout
Inhaltsverzeichnis
1;Cover;1 2;Contents;14 3;Preface;6 4;Foreword to the second edition;8 5;Contributors;10 6;Chapter 1. Epidemiology;28 6.1;Introduction;28 6.2;Diagnosis of asthma;28 6.3;Asthma in children;29 6.4;Factors influencing development of childhood asthma;32 6.5;Childhood asthma and AHR;38 6.6;Prognosis of childhood asthma;38 6.7;Asthma in adults;39 6.8;AHR in adults;41 6.9;Risk factors for adult asthma;42 6.10;Evidence for increasing severity of asthma;43 6.11;Mortality from asthma;44 6.12;Risk factors for asthma mortality;46 6.13;References;48 7;Chapter 2. Genetics;62 7.1;Introduction;62 7.2;Methods of finding disease genes in asthma;62 7.3;Problems in genetic studies of asthma;64 7.4;Modes of inheritance of atopy, BHR and asthma;64 7.5;Genetic studies of atopy and asthma;65 7.6;Genetic studies of BHR and asthma;68 7.7;Conclusion;70 7.8;References;71 8;Chapter 3. Airway Pathology in Asthma;74 8.1;Introduction;74 8.2;Sputum and bronchoalveolar lavage;75 8.3;Appearances at post-mortem;75 8.4;Loss of surface epithelium;76 8.5;Thickening of the epithelial 'basement membrane';78 8.6;Increased numbers of mucus-secreting cells;78 8.7;Enlargement of bronchial smooth muscle mass;80 8.8;Bronchial vasculature, congestion and oedema;83 8.9;Recruitment of inflammatory cells;84 8.10;Airway wall nerves;85 8.11;Conclusions;86 8.12;Acknowledgements;87 8.13;References;87 9;Chapter 4. Physiology;92 9.1;Introduction;92 9.2;Factors restricting and amplifying induced airway narrowing in vivo;92 9.3;Sites of airway narrowing in asthma;96 9.4;Effects of posture and sleep on airway function;103 9.5;Response to increasing severity of airway narrowing;104 9.6;Conclusions;110 9.7;References;110 10;Chapter 5. Airway Smooth Muscle Cells: Structure and Function;116 10.1;Introduction;116 10.2;Morphology;116 10.3;Ion channels;123 10.4;Phosphatidylinositides and calcium;127 10.5;Physiological mechanisms;128 10.6;Conclusion;132 10.7;References;133 11;Chapter 6. Mast Cells and Basophils;140 11.1;Introduction
;140 11.2;Mast cell heterogeneity;141 11.3;Mast cells. basophils and adhesion molecules;142 11.4;Distribution and morphology of human lung mast cells;143 11.5;BAL in extrinsic asthma;144 11.6;Immunologically induced mediator release;145 11.7;BAL mast cells steroid therapy in asthma;147 11.8;Antiasthmatic drugs and the inhibition of histamine release from pulmonary mast cells;147 11.9;Role of basophils in allergy and asthma;148 11.10;Role of mast cells in early asthmatic reactions;149 11.11;Role of mast cells in late asthmatic reactions and cytokine production;149 11.12;Acknowledgements;150 11.13;References;150 12;Chapter 7. Monocytes, Macrophages and Dendritic Cells;154 12.1;Introduction;154 12.2;Role of mononuclear phagocytes in inflammatory mechanisms of asthmatic disease;155 12.3;Changes in phenotype and function of monocytes and macrophages in asthma;155 12.4;Effects of glucocorticoids on monocyte/macrophage function;161 12.5;Conclusion;163 12.6;References;164 13;Chapter 8. Eosinophils;168 13.1;Introduction;168 13.2;Biochemistry and function;169 13.3;Receptors and degranulation;174 13.4;Mechanisms of eosinophil accumulation;175 13.5;The eosinophil in asthma;176 13.6;Monitoring of asthma by eosinophil markers;177 13.7;Pharmacological control of the eosinophil;177 13.8;Conclusions;178 13.9;References;178 14;Chapter 9. Lymphocytes;186 14.1;Introduction;186 14.2;Lymphocytes are strongly implicated in the pathogenesis of asthma;188 14.3;Overview of lymphocyte responses to inhaled foreign antigens;190 14.4;Perspective: defects in termination of immune responses may cause chronic disease;203 14.5;Acknowledgement;204 14.6;References;204 15;Chapter 10. Epithelial Cells;214 15.1;Introduction;214 15.2;Morphology of the airway epithelium;214 15.3;Airway epithelium and hyperresponsiveness;217 15.4;Epithelial cell-derived mediators;217 15.5;Adhesion molecules and the airway epithelium;221 15.6;Immunoregulation;222 15.7;Culture of human airway epithelial cells in vitro;223 15.
8;Summary;224 15.9;References;226 16;Chapter 11. Pathophysiology of Airway Mucus Secretion in Asthma;232 16.1;Introduction;232 16.2;Airway mucus;232 16.3;Airway mucus-secreting cells;234 16.4;Mucus abnormalities in asthma;235 16.5;Consequences of airway mucus hypersecretion and hyperviscosity;240 16.6;Inducers of airway mucus secretion;243 16.7;Pharmacological treatment of mucus hypersecretion in asthma;245 16.8;Conclusions;248 16.9;Acknowledgements;249 16.10;References;249 17;Chapter 12. Tracheobronchial Circulation;256 17.1;Introduction;256 17.2;Organization and control of the tracheobronchial circulation;256 17.3;Role of the tracheobronchial circulation in asthma;258 17.4;Conclusion;261 17.5;References;261 18;Chapter 13. Adhesion Molecules;266 18.1;Introduction;266 18.2;Leucocyte adhesion receptors;267 18.3;Expression of adhesion receptors in allergic disease;269 18.4;Role of adhesion receptors in leucocyte migration in allergic disease;271 18.5;In vivo studies of adhesion receptor antagonists in models of allergic inflammation;273 18.6;Summary;273 18.7;References;275 19;Chapter 14. Microvascular-Epithelial Exudation of Plasma;280 19.1;Introduction;280 19.2;Exudation pathways;281 19.3;Acute challenge-induced microvascular-epithelial exudation;284 19.4;Mucosal exudation of plasma in disease;286 19.5;Roles of exuded plasma;288 19.6;On the inward perviousness in asthma;289 19.7;Airway epithelial restitution in a plasma-derived gel;290 19.8;References;292 20;Chapter 15. Prostaglandins and Thromboxane;296 20.1;Introduction;296 20.2;Arachidonic acid metabolism;297 20.3;Cyclooxygenase products;298 20.4;Prostaglandin and thromboxane receptors;298 20.5;Role of COX products in asthma;299 20.6;Stimulatory prostaglandins and thromboxane;300 20.7;Inhibitory prostaglandins;302 20.8;Conclusions;304 20.9;References;305 21;Chapter 16. Cysteinyl Leukotrienes;308 21.1;Introduction;308 21.2;Formation and metabilism of the leukotrienes;308 21.3;Leukotrienes in asthma;310 21.4;Conclus
ions;316 21.5;References;317 22;Chapter 17. Kinins;324 22.1;Introduction;324 22.2;Structure, formation and metabolism;325 22.3;Receptors and general pharmacological properties;327 22.4;Kinin formation in airway inflammation;328 22.5;Effects of kinins on airways;328 22.6;Mechanisms of action;329 22.7;Summary;330 22.8;Acknowledgements;331 22.9;References;331 23;Chapter 18. Chemokines;336 23.1;Introduction;336 23.2;Discovery and structure;337 23.3;Cell sources;339 23.4;Regulation;339 23.5;Chemokines as chemoattractants and cell activators;340 23.6;Chemokine receptors;343 23.7;Expression and release of chemokines in asthma;344 23.8;Conclusion;345 23.9;References;346 24;Chapter 19. Lymphokines;360 24.1;Introduction;360 24.2;Type 1 and type 2 T-cells;360 24.3;Actions of type 2 cytokines relevant to asthma;362 24.4;Evidence of T-cell cytokine production in asthma;364 24.5;T-cell cytokines in non-atopic asthma;366 24.6;Factors determining type 1 or type 2 T-cell development;367 24.7;Alteration of established type 1 or type 2 cytokine profile;367 24.8;Potential for intervention;368 24.9;Conclusion;368 24.10;References;368 25;Chapter 20. Other Mediators of Asthma;374 25.1;Introduction;374 25.2;Histamine;374 25.3;Platelet-activating factor;377 25.4;Oxygen radicals;380 25.5;Complement;382 25.6;Serotonin;384 25.7;Eosinophil proteins;385 25.8;Endothelin;385 25.9;References;388 26;Chapter 21. Nitric Oxide;400 26.1;Introduction;400 26.2;Generation of NO;400 26.3;Effects of NO on airway function;402 26.4;Exhaled NO;406 26.5;Therapeutic implications;413 26.6;References;414 27;Chapter 22. Neural Control of Airway Function in Asthma;420 27.1;Introduction;420 27.2;Afferent nerves;423 27.3;Parasympathetic nerves;424 27.4;Adrenergic control;430 27.5;References;434 28;Chapter 23. Humoral Control of Airway Tone;440 28.1;Introduction;440 28.2;Vasoactive peptides;440 28.3;Hormones;444 28.4;Circulating inflammatory mediators;446 28.5;Oxygen and carbon dioxide;446 28.6;Conclusions;448 28.7;Refe
rences;448 29;Chapter 24. NANC Nerves and Neuropeptides;454 29.1;Introduction;454 29.2;Non-adrenergic non-cholinergic (NANC) nerves;456 29.3;VIP and related peptides;459 29.4;Tachykinins;465 29.5;CGRP;467 29.6;Neurogenic inflammation;469 29.7;Other neuropeptides;475 29.8;Role of neuropeptides in asthma;477 29.9;References;478 30;Chapter 25. Transcription Factors;490 30.1;Basal and regulated transcription;490 30.2;NF-kB, the Rel family of proteins and lkB proteins;491 30.3;AP-1 and related transcription factors;495 30.4;CCAAT/enhancer-binding proteins and NF-IL-6;495 30.5;JAK-STAT pathway;496 30.6;Glucocorticoid receptors;497 30.7;Cross-talk between transcription factors and their transduction pathways;497 30.8;Transcription factors in asthma;500 30.9;References;502 31;Chapter 26. Airway Remodelling;506 31.1;Introduction;506 31.2;Structural changes in the airway walls in asthma;506 31.3;Extracellular matrix;509 31.4;Smooth muscle;512 31.5;Summary;514 31.6;Acknowledgements;514 31.7;References;515 32;Chapter 27. Pathophysiology of Asthma;518 32.1;Introduction;518 32.2;Asthma as an inflammatory disease;519 32.3;Inflammatory cells;520 32.4;Structural cells;522 32.5;Inflammatory mediators;524 32.6;Effects of inflammation;526 32.7;Transcription factors;530 32.8;Anti-inflammatory mechanisms in asthma;530 32.9;Genetic influences;531 32.10;Unanswered questions;532 32.11;References;534 33;Chapter 28. Allergens;538 33.1;Introduction;538 33.2;Atopy;539 33.3;Inhaled allergens;539 33.4;Allergic bronchopulmonary aspergillosis;549 33.5;Ingested/injected allergens;551 33.6;Acknowledgements;551 33.7;References;551 34;Chapter 29. Occupational Asthma;560 34.1;Introduction: initiators and provokers of asthma;560 34.2;Irritant-induced asthma;561 34.3;Causes of hypersensitivity-induced occupational asthma;562 34.4;Importance of hypersensitivity-induced occupational asthma;563 34.5;Occupational asthma and hypersensitivity;563 34.6;Determinants of hypersensitivity-induced occupational asthma
;565 34.7;Diagnosis of hypersensitivity-induced occupational asthma;567 34.8;Investigation of hypersensitivity-induced occupational asthma;568 34.9;Outcome of hypersensitivity-induced occupational asthma;572 34.10;Management of occupational asthma;573 34.11;References;574 35;Chapter 30. Infections;578 35.1;Introduction;578 35.2;Epidemiology of respiratory infections and wheezing;578 35.3;Mechanisms of virus-induced airway hyperresponsiveness;587 35.4;Summary;595 35.5;Acknowledgements;595 35.6;References;595 36;Chapter 31. Asthma Provoked by Exercise, Hyperventilation and the Inhalation of Non-isotonic Aerosols;600 36.1;Introduction;600 36.2;Respiratory water loss and conditioning of inspired air;601 36.3;Role of the bronchial circulation;603 36.4;Generation and deposition of non-isotonic aerosols in the respiratory tract;605 36.5;Comparison between challenge with exercise and hyperventilation and challenge with non-isotonic aerosols;605 36.6;Mechanisms by which a change in osmolarity and airway drying induce airway narrowing;607 36.7;Effect of pharmacological agents;609 36.8;References;612 37;Chapter 32. Atmospheric Pollutants;620 37.1;Ozone;620 37.2;Nitrogen dioxide;622 37.3;Sulphur dioxide;623 37.4;Summary;624 37.5;References;624 38;Chapter 33. Drug-induced Asthma;628 38.1;B-Blockers;628 38.2;Additives;631 38.3;ACE inhibitors;632 38.4;Local anaesthetics;633 38.5;Other drugs;633 38.6;References;634 39;Chapter 34. Aspirin-induced Asthma;638 39.1;History and definition;638 39.2;Pathogenesis;639 39.3;Clinical presentation;642 39.4;Diagnosis;643 39.5;Differential diagnosis;644 39.6;Prevention and treatment;644 39.7;References;645 40;Chapter 35. Allergen Avoidance;648 40.1;Introduction;648 40.2;Indoor allergens as a cause of asthma;649 40.3;Primary sensitization;652 40.4;Allergen exposure and asthma severity;653 40.5;Are threshold values useful?;654 40.6;Allergen avoidance;656 40.7;Allergen Avoidance: Practical Measures;664 40.8;Allergen avoidance in asthma prevention;6
71 40.9;Conclusions;671 40.10;References;672 41;Chapter 36. B-Adrenoceptor Agonists;682 41.1;Introduction;682 41.2;Molecular pharmacology;682 41.3;Clinical pharmacology;689 41.4;Differences between B-agonists;692 41.5;Efficacy and safety of inhaled B-agonists;693 41.6;Oral B-agonists;700 41.7;References;701 42;Chapter 37. Anticholinergic Bronchodilators;708 42.1;Introduction;708 42.2;Rationale for use of anticholinergic bronchodilators;708 42.3;Pharmacology;710 42.4;Clinical efficacy;712 42.5;Side-effects;716 42.6;Clinical recommendations;717 42.7;References;717 43;Chapter 38. Theophylline;720 43.1;Introduction;720 43.2;Historical background;720 43.3;Chemistry;721 43.4;Molecular mechanisms of action;721 43.5;Effects;724 43.6;Pharmacokinetics;727 43.7;Routes of administration;728 43.8;Clinical use;729 43.9;Side-effects;732 43.10;Future of theophylline;732 43.11;References;733 44;Chapter 39. Cromones;738 44.1;Introduction;738 44.2;Pharmacokinetics;739 44.3;Effects on inflammatory cells and nerves;739 44.4;Evidence for anti-inflammatory actions;742 44.5;Mechanisms of action;742 44.6;Clinical studies in asthma;743 44.7;References;749 45;Chapter 40. Glucocorticosteroids;756 45.1;Introduction;756 45.2;Molecular mechanisms;756 45.3;Effects on cell function;763 45.4;Effects on asthmatic inflammation;766 45.5;Clinical efficacy of inhaled steroids;767 45.6;Pharmacokinetics;769 45.7;Side-effects of inhaled steroids;770 45.8;Clinical use of inhaled steroids;776 45.9;Systemic steroids;777 45.10;Glucocorticoid resistance in asthma;779 45.11;References;786 46;Chapter 41. Mediator Antagonists;798 46.1;Introduction;798 46.2;Antihistamines;798 46.3;Leukotriene antagonists;799 46.4;Prostaglandin inhibitors;803 46.5;Platelet-activating factor (PAF) antagonists;804 46.6;Phospholipase inhibitors;805 46.7;Bradykinin antagonists;806 46.8;Antioxidants;806 46.9;Adenosine antagonists;807 46.10;NO synthase inhibitors;807 46.11;Endothelin antagonists;808 46.12;Basic protein inhibitors and hepar
in;808 46.13;Inflammatory enzyme inhibitors;808 46.14;Combined inhibitors;809 46.15;References;809 47;Chapter 42. Immunomodulators;814 47.1;Clinical need;814 47.2;Immunosuppressive therapy in asthma;815 47.3;Newer immunosuppressive agents;821 47.4;Conclusions;822 47.5;References;822 48;Chapter 43. Future Therapies for Asthma;826 48.1;Introduction;826 48.2;New bronchodilators;827 48.3;Mediator antagonists;832 48.4;Cytokines and cytokine inhibitors;836 48.5;Anti-inflammatory drugs;838 48.6;Gene therapy;844 48.7;Conclusions;845 48.8;References;845 49;Chapter 44. Management of Severe Asthma;852 49.1;Introduction;852 49.2;General assessment and management;852 49.3;Specific treatment for severe acute asthma;854 49.4;Assisted ventilation;858 49.5;Management of catastrophic asthma;859 49.6;Other measures;861 49.7;Summary;862 49.8;References;862 50;Chapter 45. Management of Asthma in Adults;866 50.1;Introduction;866 50.2;Classificationofasthma for purposes ofmanagement;867 50.3;Aims of management;868 50.4;Asthma management plan;868 50.5;Treatment of the patient with severe persistent asthma;883 50.6;Likely future changes to management;884 50.7;References;885 51;Chapter 46. Asthma in Children;890 51.1;Introduction;890 51.2;Anatomical and physiological factors;891 51.3;Wheezing illness;891 51.4;Natural history;892 51.5;Risk factors and prevention;894 51.6;Growth;895 51.7;Pharmacokinetics and pharmacodynamics;895 51.8;Assessment of the clinical condition;896 51.9;Irreversible airway obstruction;899 51.10;Treatment;900 51.11;Special age groups;914 51.12;Severe acute asthma/status asthmaticus;915 51.13;Immunotherapy;919 51.14;General measures;920 51.15;References;921 52;Chapter 47. Pharmacoeconomics of Asthma Treatments;934 52.1;Introduction;934 52.2;Principles and applications of pharmaco economics;935 52.3;Cost-benefit analysis;936 52.4;Cost-effectiveness analysis;937 52.5;Asthma outcomes for pharmacoeconomic evaluation;938 52.6;Pharmacoeconomics of asthma pharmacotherapy;938 5
2.7;Conclusions;955 52.8;References;945 53;Chapter 48. Education and Self-management;948 53.1;Introduction;948 53.2;Health professional education and guidelines;948 53.3;Compliance;949 53.4;How do we improve communication?;950 53.5;Self-management;953 53.6;Conclusion;955 53.7;References;955 54;Index;958 55;Color Plate Section;354